Mylan gets marketing rights for MS drug
Notice: Undefined variable: article_ad_placement3 in /usr/web/cs-washington.ogdennews.com/wp-content/themes/News_Core_2023_WashCluster/single.php on line 128
Generic pharmaceutical giant Mylan N.V. and Israeli firm Mapi Pharma Ltd. are partnering to develop and commercialize an injectable drug to treat multiple sclerosis.
Mylan, with administrative headquarters in Southpointe II, is acquiring global marketing rights to the product GA Depot, the local company reported in a news release.
Patients with relapsing-remitting multiple sclerosis will inject the drug once monthly.
An estimated 2.3 million worldwide have the degenerative disease of the nervous system.
Mylan President Rajiv Malik said in the news release: “Improving the lives of MS patients around the world is one of Mylan’s primary goals. We recognize that medication convenience is very important to the MS community, and we believe that GA Depot, once approved, will provide an important and welcomed treatment option.”